Research advances in radiotherapy combined with immunotherapy for cancer
Sui Xin,Zhao Dan,Lin Hongmei,Zhu Guangying
Department of Radiation Oncology,Peking University Cancer Hospital and Institute,Key Laboratory of Ministry of Education for Carcinogenesis and Translational Research,Beijing 100142,China
Abstract： Radiotherapy not only acts as an important local treatment of cancer, but also plays a key role in regulation of immune function. Radiotherapy regulates anti-tumor immune responses by promoting the generation of neoantigens, regulating the release of cytokine, and enhancing the sensitivity of tumor to cell-mediated immunity. Recently, several studies and clinical practice reported the abscopal effect in some patients undergoing radiotherapy combined with immunotherapy, which showed partial or complete response of metastases outside the irradiation field, suggesting the combination therapy as a promising strategy. However, further studies are needed for the understanding of the mechanism and influencing factors for immunity such as radiation dose and fractionation scheme. This paper reviews the research advances in the mechanism of radiotherapy-immunotherapy interaction and the combination therapy for cancer.
Sui Xin,Zhao Dan,Lin Hongmei et al. Research advances in radiotherapy combined with immunotherapy for cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(10): 1135-1138.
[1] Larkin J,Chiarion-Sileni V,Gonzalez R,et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma[J].N Engl J Med,2015,373(1):23-34.DOI:10.1056/NEJMoa1504030. [2] Brahmer J,Reckamp KL,Baas P,et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.DOI:10.1056/NEJMoa1504627. [3] Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J].N Engl J Med,2012,366(10):925-931.DOI:10.1056/NEJMoa1112824. [4] 于金明,滕菲菲.放疗与免疫治疗联合应用的相关机制及研究进展[J].中国肿瘤临床,2014,41(9):547-550.DOI:10.3969/j.issn.1000-8179.20140527. Yu JM,Teng FF.Mechanism and research progress of combined application of radiotherapy and immunotherapy[J].Chin J Clin Oncol,2014,41(9):547-550.DOI:10.3969/j.issn.1000-8179.20140527. [5] Schreiber RD,Old LJ,Smyth MJ.Cancer immunoediting:integrating immunity′s roles in cancer suppression and promotion[J].Science,2011,331(6024):1565-1570.DOI:10.1126/science.1203486. [6] Sims GP,Rowe DC,Rietdijk ST,et al. HMGB1 and RAGE in inflammation and cancer[J].Annu Rev Immunol,2010,28(1):367-388.DOI:10.1146/annurev.immunol.021908.132603. [7] Koebel CM,Vermi W,Swann JB,et al. Adaptive immunity maintains occult cancer in an equilibrium state[J].Nature,2007,450(7171):903-907.DOI:10.1038/nature06309. [8] Khong HT,Restifo NP.Natural selection of tumor variants in the generation of "tumor escape" phenotypes[J].Nat Immunol,2002,3(11):999-1005.DOI:10.1038/ni1102-999. [9] Gilboa E.The makings of a tumor rejection antigen[J].Immunity,1999,11(3):263-270.DOI:10.1016/S1074-7613(00)80101-6. [10] Schumacher TN,Schreiber RD.Neoantigens in cancer immunotherapy[J].Science,2015,348(6230):69-74.DOI:10.1126/science.aaa4971. [11] Segal NH,Parsons DW,Peggs KS,et al. Epitope landscape in breast and colorectal cancer[J].Cancer Res,2008,68(3):889-892.DOI:10.1158/0008-5472.CAN-07-3095. [12] Sharma P,Allison JP.The future of immune checkpoint therapy[J].Science,2015,348(6230):56-61.DOI:10.1126/science.aaa8172. [13] Leach DR,Krummel MF,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade[J].Science,1996,271(5256):1734-1736.DOI:10.1126/science.271.5256.1734. [14] Freeman GJ,Long AJ,Iwai Y,et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034.DOI:10.1084/jem.192.7.1027. [15] Hodi FS,O′Day SJ,McDermott DF,et al. Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723.DOI:10.1056/NEJMoa1003466. [16] Topalian SL,Hodi FS,Brahmer JR,et al. Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.DOI:10.1056/NEJMoa1200690. [17] Weber JS,D′Angelo SP,Minor D,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised,controlled,open-label,phase 3 trial[J].Lancet Oncol,2015,16(4):375-384.DOI:10.1016/S1470-2045(15)70076-8. [18] Garon EB,Rizvi NA,Hui R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.DOI:10.1056/NEJMoa1501824. [19] Hill-Kayser CE,Plastaras JP,Tochner Z,et al. TBI during BM and SCT:review of the past,discussion of the present and consideration of future directions[J].Bone Marrow Transplant,2011,46(4):475-484.DOI:10.1038/bmt.2010.280. [20] Formenti SC,Demaria S.Combining radiotherapy and cancer immunotherapy:a paradigm shift[J].J Natl Cancer Inst,2013,105(4):256-265.DOI:10.1093/jnci/djs629. [21] Gardai SJ,McPhillips KA,Frasch SC,et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte[J].Cell,2005,123(2):321-334.DOI:10.1016/j.cell.2005.08.032. [22] Obeid M,Tesniere A,Ghiringhelli F,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death[J].Nat Med,2007,13(1):54-61.DOI:10.1038/nm1523. [23] Apetoh L,Ghiringhelli F,Tesniere A,et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J].Nat Med,2007,13(9):1050-1059.DOI:10.1038/nm1622. [24] Ghiringhelli F,Apetoh L,Tesniere A,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors[J].Nat Med,2009,15(10):1170-1178.DOI:10.1038/nm.2028. [25] Adinolfi E,Capece M,Franceschini A,et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7[J].Cancer Res,2015,75(4):635-644.DOI:10.1158/0008-5472.CAN-14-1259. [26] Lugade AA,Sorensen EW,Gerber SA,et al. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity[J].J Immunol,2008,180(5):3132-3139.DOI:10.4049/jimmunol.180.5.3132. [27] Matsumura S,Wang B,Kawashima N,et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells[J].J Immunol,2008,181(5):3099-3107.DOI:10.4049/jimmunol.181.5.3099. [28] Reits EA,Hodge JW,Herberts CA,et al. Radiation modulates the peptide repertoire,enhances MHC class I expression,and induces successful antitumor immunotherapy[J].J Exp Med,2006,203(5):1259-1271.DOI:10.1084/jem.20052494. [29] Chakraborty M,Abrams SI,Camphausen K,et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy[J].J Immunol,2003,170(12):6338-6347.DOI:10.4049/jimmunol.170.12.6338. [30] Kim JY,Son YO,Park SW,et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation[J].Exp Mol Med,2006,38(5):474-484.DOI:10.1038/emm.2006.56. [31] Naiki Y,Michelsen KS,Zhang WX,et al. Transforming growth factor-β differentially inhibits MyD88-dependent,but not TRAM-and TRIF-dependent,lipopolysaccharide-induced TLR4 signaling[J].J Biol Chem,2005,280(7):5491-5495.DOI:10.1074/jbc. C400503200. [32] Wrzesinski SH,Wan YY,Flavell RA.Transforming growth factor-β and the immune response:implications for anticancer therapy[J].Clin Cancer Res,2007,13(18):5262-5270.DOI:10.1158/1078-0432.CCR-07-1157. [33] Young KH,Newell P,Cottam B,et al. TGFβ Inhibition prior to Hypofractionated radiation enhances efficacy in preclinical models[J].Cancer Immunol Res,2014,2(10):1011-1022.DOI:10.1158/2326-6066.CIR-13-0207. [34] Klug F,Prakash H,Huber PE,et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy[J].Cancer Cell,2013,24(5):589-602.DOI:10.1016/j.ccr.2013.09.014. [35] Lugade AA,Moran JP,Gerber SA,et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor[J].J Immunol,2005,174(12):7516-7523.DOI:10.4049/jimmunol.174.12.7516. [36] Lee Y,Auh SL,Wang YG,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870. [37] Dewan MZ,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J].Clin Cancer Res,2009,15(17):5379-5388.DOI:10.1158/1078-0432.CCR-09-0265. [38] Kulzer L,Rubner Y,Deloch L,et al. Norm-and hypo-fractionated radiotherapy is capable of activating human dendritic cells[J].J Immunotoxicol,2014,11(3):328-336.DOI:10.3109/1547691X.2014.880533. [39] John-Aryankalayil M,Palayoor ST,Cerna D,et al. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting[J].Radiat Res,2010,174(4):446-458.DOI:10.1667/RR2105.1. [40] Rizvi NA,Hellmann MD,Snyder A,et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.DOI:10.1126/science.aaa1348. [41] Sharabi AB,Nirschl CJ,Kochel CM,et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J].Cancer Immunol Res,2015,3(4):345-355.DOI:10.1158/2326-6066.CIR-14-0196. [42] Stamell EF,Wolchok JD,Gnjatic S,et al. The abscopal effect associated with a systemic anti-melanoma immune response[J].Int J Radiat Oncol Biol Phys,2013,85(2):293-295.DOI:10.1016/j.ijrobp.2012.03.017. [43] Twyman-Saint Victor C,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.DOI:10.1038/nature14292.
2016, Vol. 25 
